ยาลดน้ำหนักในปัจจุบัน

  • วีระเดช พิศประเสริฐ สาขาวิชาโภชนวิทยาคลินิก ภาควิชาอายุรศาสตร์ คณะแพทยศาสตร์ มหาวิทยาลัยขอนแก่น

บทคัดย่อ

No available

Downloads

Download data is not yet available.

เอกสารอ้างอิง

National Institutes of Health, National Heart, Lung, and Blood Institute: Clinical guidelines on the identification, evaluation, and treatment of overweight and

obesity in adults. Bethesda, MD: US Department of Health and Human Services, 1998.

สำนักงานสำรวจสุขภาพประชาชนไทย. รายงานการสำรวจสุขภาพประชากรโดยการตรวจร่างกายครั้งที่ 4 พ.ศ. 2551-2 โดย: นายแพทย์วิชัย เอกพลากร, บรรณาธิการ. นนทบุรี: เดอะกราฟิโกซิสเต็มส์จำกัด; 2553:. หน้า 127-34.

Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2015;100:342-362.

Li Z, Maglione M, Tu W, et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med2005;142:532-46.

Padwal RS, Li SK, Lau DCW. Long-term pharmacotherapy for obesity and overweight. Cochrane Database of Systemic Reviews 2004;(3):CD004094.

Rucker D, Padwal R, Li SK, Curioni C, Lau DCW. Long-term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335:1194-203.

Franz MJ, VanWormer JJ, Crain AL, et al. Weightloss outcomes: a systemic review and meta-analysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc 2007;107:1755-1767.

Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med 2015;373(1):11-22.

Wadden T, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE

maintenance randomized study. Int J Obes (Lond) 2013;37:1443-51

Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjoth TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE

diabetes randomized clinical trial. JAMA 2015; 314(7):687-99.

Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe

obstructive sleep apnea: the SCALE sleep apnea randomized clinical trial. Int J Obes (Lond) 2016 Mar 23. [Epub ahead of print]

Kramer CK, Leitao CB, Pinto LC, Canani LH, Azevedo MJ, Gross JL. Efficacy and safety of topiramate on weight loss: a meta-analysis of randomized controlled

trials. Obes Rev 2011;12(5):e338-47.

Allison DB, Gadde KM, William Timothy Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial

(EQUIP). Obesity 2011;20:330-42.

Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.Lancet 2011;377:1341-52.

Garvey WT, Ryan DH, Look M, Gadde KM, Allison DB, Peterson CA, et al. Two-year sustained weight loss and metabolic benefits with controlled-release

phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr 2012;95:

-308.

Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med 2010;363(3):245-56.

Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obeseand overweight adults: the BLOSSOM trial. J Clin

Endocrinol Metab 2011;96(10):3067-77.

OûNeil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOMDM

study. Obesity (Silver Spring) 2012;20(7):1426-36.

Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 2010;376:595-605.

Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/ bupropion SR combination therapy as an adjunct to behavior modification: the

COR-BMOD trial. Obesity 2011;19(1):110-20.

Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/ bupropion SR on weight and obesity-related risk factors (COR-II). Obesity

;21(5):935-43.

Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/ bupropion sustainedrelease combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013;36(12):4022-9.

Bray GA, Greenway FL. Pharmacological treatment of the overweight patient. Pharmacol Rev 2007; 59(2): 151-84.

เผยแพร่แล้ว
2020-06-29
การอ้างอิงบทความ
ประเภทบทความ
บทความพิเศษ

Most read articles by the same author(s)